Pragmatic clinical trial to assess the utility of SLCO1B1, ABCG2, and CYP2C9 preemtive genotyping and pharmacogenetics training on the incidence of musculoskeletal adverse reactions in patients treated with statins in primary and specialized care.
- Conditions
- Cardiovascular risk which needs primary or secundary prevention with statinsMedDRA version: 21.0Level: LLTClassification code: 10020604Term: Hypercholesterolemia Class: 10027433MedDRA version: 20.0Level: PTClassification code: 10077965Term: Primary hypercholesterolaemia Class: 100000004850MedDRA version: 20.0Level: PTClassification code: 10020603Term: Hypercholesterolaemia Class: 100000004861Therapeutic area: Phenomena and Processes [G] - Musculoskeletal and Neural Physiological Phenomena [G11]Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Therapeutic area: Phenomena and Processes [G] - Genetic Phenomena [G05]
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 1000
Adults, with any type of cardiovascular risk (high, moderate or low): a)In which it is indicated statins as a treatment at any dose. b)Pacients who must be outpatients, recruited in a health care centre (primary attention) or in hospitals (primary or secundary prevention). c)Pacients who must have never taken statins or who have started statin treatment less tan 15 days ago, or who had their statin dose increased or changed to a more potent statin due to bad control of LDL levels in the last 15 days. d)Patients who have to give their inform consent form written
a)Pacients who statins are not prescribed as standard clinical practice. b)Pacients who suffer a malignant or terminal disease whose live expectancy will be less than 6 months. c)Pacients who have statins contraindicated for treatment d)Pregnant or breast-feeding patients.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method